Sold under brand names including Wegovy and Ozempic, semaglutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), hence the technical term for it is a GLP-1 receptor agonist.

Ozempic, Wegovy and Other Drugs Are Among 15 Selected for Medicare's Price Negotiations WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to ...

Your trusted source for the latest news delivered weekdays from the team at U.S. News and World Report. Sign in to manage your newsletters » Sign up to receive the latest updates from U.S News ...

Since its online debut late last month, the one-minute ad pitching the company’s legal knockoff of the weight-loss drug Wegovy has stoked the controversy over the high costs of a new generation ...

In addition to Wegovy, incretin mimetics FDA-approved for chronic weight management include Saxenda (liraglutide), also made by Novo Nordisk, and Zepbound (tirzepatide), produced by Fortune 500 ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year ...

WASHINGTON — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug ...

Novo Nordisk reported soaring sales for weight loss drug Wegovy (James Manning/PA) Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo ...

In addition to Wegovy, its sister drug Ozempic, indicated for diabetes, and NVO’s oral GLP-1 agonist Rybelsus have also been selected for the negotiation round. Other drugs included in the list ...